- Home
- OGEN vs NTBL Comparison
OGEN vs NTBL Comparison
Compare OGEN & NTBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- NTBL
- Stock Information
- Founded
- OGEN 1996
- NTBL 2000
- Country
- OGEN United States
- NTBL United States
- Employees
- OGEN N/A
- NTBL N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- NTBL Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- NTBL Health Care
- Exchange
- OGEN Nasdaq
- NTBL Nasdaq
- Market Cap
- OGEN 4.5M
- NTBL 4.6M
- IPO Year
- OGEN N/A
- NTBL N/A
- Fundamental
- Price
- OGEN $0.34
- NTBL $0.25
- Analyst Decision
- OGEN
- NTBL Buy
- Analyst Count
- OGEN 0
- NTBL 2
- Target Price
- OGEN N/A
- NTBL $5.00
- AVG Volume (30 Days)
- OGEN 389.1K
- NTBL 8.1M
- Earning Date
- OGEN 11-07-2024
- NTBL 11-12-2024
- Dividend Yield
- OGEN N/A
- NTBL N/A
- EPS Growth
- OGEN N/A
- NTBL N/A
- EPS
- OGEN N/A
- NTBL N/A
- Revenue
- OGEN $7,466.00
- NTBL $313,000.00
- Revenue This Year
- OGEN N/A
- NTBL N/A
- Revenue Next Year
- OGEN N/A
- NTBL N/A
- P/E Ratio
- OGEN N/A
- NTBL N/A
- Revenue Growth
- OGEN N/A
- NTBL 3812.50
- 52 Week Low
- OGEN $0.29
- NTBL $0.22
- 52 Week High
- OGEN $7.74
- NTBL $4.24
- Technical
- Relative Strength Index (RSI)
- OGEN 37.15
- NTBL 35.14
- Support Level
- OGEN $0.29
- NTBL $0.28
- Resistance Level
- OGEN $0.45
- NTBL $0.37
- Average True Range (ATR)
- OGEN 0.04
- NTBL 0.06
- MACD
- OGEN 0.02
- NTBL -0.01
- Stochastic Oscillator
- OGEN 28.88
- NTBL 6.26
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About NTBL Notable Labs Ltd.
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.